Journals / Turkish Journal of Pharmaceutical Sciences / 2012 / Cilt: 9 - Sayı: 2

INDOLE DERIVATIVES AS SRC FAMILY KINASE AND GLUTATHIONE S-TRANSFERASE INHIBITORS: EVALUATION OF THEIR SELECTIVITY AND DRUG RESISTANCE PROPERTIES

Glutatyon S-transferaz ve Src Ailesi Kinaz İnhibitörü İndol Türevleri: Seletivite ve İlaç Rezistans Özelliklerinin Değerlendirilmesi

Pages
151–160
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The compounds 8f and 8h are also showed reasonable inhibitory levels of GSTs with IC50s of 161.1, and 272.2 µM, However inhibition profiles of compounds are not found suitable for further developments.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The increased activity levels of Glutathione S-transferases (GST) have been correlated with human cancers and the anticancer drug resistance.
📊
Key Findings & Data:The recent efforts of our laboratory to design and synthesize novel c-Src inhibitors were accomplished with four indole-3-amine derivatives substituted at N1 and C5 (8c, 8f, 8g, and 8h), with IC50s values of 4.69, 74.79, 75.06, and 84.23 µM, respectively.
💡
Conclusion & Impact:The compounds 8f and 8h are also showed reasonable inhibitory levels of GSTs with IC50s of 161.1, and 272.2 µM, However inhibition profiles of compounds are not found suitable for further developments.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

The increased activity levels of Glutathione S-transferases (GST) have been correlated with human cancers and the anticancer drug resistance. Similarly, Src family kinases (SFKs), has been reported in many cancers including breast, colon, lung, and skin with relatively high catalytic activity. Therefore, the inhibition of both GSTs and Src may enhance the therapeutic efficacy of chemotherapeutics by increasing the selectivity and resistance of compounds. The recent efforts of our laboratory to design and synthesize novel c-Src inhibitors were accomplished with four indole-3-amine derivatives substituted at N1 and C5 (8c, 8f, 8g, and 8h), with IC50s values of 4.69, 74.79, 75.06, and 84.23 µM, respectively. In this present work, the inhibitory activities against SFKs (Lyn, Hck, Fyn), GSTs and selectivity studies of these compounds were performed. Among the compounds, 8c and 8g are found the best GST inhibitors with IC50s values of 120.1, and 67.33 µM, respectively, and are reported as the Src inhibitors with dual action. The compounds 8f and 8h are also showed reasonable inhibitory levels of GSTs with IC50s of 161.1, and 272.2 µM, However inhibition profiles of compounds are not found suitable for further developments.

Özet

Artan glutation s-transferaz (GST) aktivitesi insanlarda görülen kanserler ve antikanser ilaç direnci ile ilişkilidir. Benzer şeklilde, Src ailesi kinazların (SFK) meme, kolon, akciğer ve deri gibi pek çok kanser türünde yüksek katalitik aktivitesi olduğu rapor edilmiştir. Bu nedenle, GST ve Src'ın her ikisinin inhibisyonu, kemoterapötiklerin seçici ve dayanıklı olmasını sağlayarak terapötik etkinliğini artırabilir. Son yıllarda laboratuvarımızda gerçekleştirilen c-Src inhibitörü bileşiklerin tasarımı ve sentezi çabaları ile IC50 değeri sırayla 4.69, 74.79, 75.06 ve 84.23 µM olan N1 ve C5 sübstitüe indol-3-amin türevi dört bileşik (8c, 8f, 8g ve 8h) başarı ile elde edilmiştir. Bu çalışmada, bu bileşiklerin SFK'lar (Lyn, Hck, Fyn) ve GST enzimlerine karşı inhibitör aktiviteleri tayin edilmeye ve Src ailesi kinazlara olan seçicilikleri saptanmaya çalışılmıştır. Bileşiklerden 8c and 8g GST enzimi için sırayla IC50 değerleri 120.1 ve 67.33 µM olan en etkin inhibitörler ve ayrıca Src inhibitör özelliklerinin olması de ikili inhibitörler olarak rapor edilmişlerdir. Bileşiklerden 8f ve 8h sırayla IC50 değerleri 161.1 ve 272.2 µM ile önemli derecede GST inhibisyonu gösterdiler. Ancak bileşiklerin bu inhibisyon profilleri ile ileri çalışmalar için uygun olmadıkları bulunmuştur.

🔖

Cite This Article

ÖLGEN, S., İŞGÖR, Y. G., KURT, Z. K., İŞGÖR, B. S. (2012). INDOLE DERIVATIVES AS SRC FAMILY KINASE AND GLUTATHIONE S-TRANSFERASE INHIBITORS: EVALUATION OF THEIR SELECTIVITY AND DRUG RESISTANCE PROPERTIES. Turkish Journal of Pharmaceutical Sciences, Cilt: 9 - Sayı: 2, 151–160. https://ajindex.com/articles/404012

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. Biscardi JS, Tice DA, Parsons SJ, c-Src, receptor tyrosine kinases, and human cancer, Adv Cancer Res 76, 61-119, 1999
  2. Martin GS, The road to Src, Oncogene 23, 7910-7917, 2004
  3. Lowell CA, Soriano P, Knockouts of Src-family kinases: stiff bones, wimpy T cells, and bad memories, Genes Dev 10, 1845-1857, 1996
  4. Bjorge JD, Jakymiw A, Fujita DJ, Selected glimpses into the activation and function of Src kinase, Oncogene 19, 5620-5635, 2000
  5. Ingley E, Src family kinases: Regulation of their activities, levels and identification of new pathways, Biochem et Biophys Acta 1784, 56-65, 2008
  6. Brown MT, Cooper JA, Regulation, substrates and functions of src, Biochim Biophys Acta 1287, 121-149, 1996
  7. Rucci N, Susa M, Teti A, Inhibition of protein kinase c-Src as a therapeutic approach for cancer and bone metastases, Anti-Cancer Agents in Med Chem 8, 342-349, 2008
  8. Schwartzberg PL, The many faces of Src: multiple functions of a prototypical tyrosine kinase, Oncogene 17, 1463-1468, l998
  9. Thomas SM, and Brugge JS, Cellular functions regulated by Src family kinases, Annu Rev Cell Dev Biol 13, 513-609, 1997
  10. Frame MC, Src in cancer: deregulation and consequences for cell behaviour, Biochim Biophys Acta 1602, 114-130, 2002
  11. Warmuth M, Damoiseaux R, Liu Y, Fabbro D, Gray N, Src family kinases: potential targets for the treatment of human cancer and leukemia, Curr Pharm Des 9, 2043-2059, 2003
  12. Belsches-Jablonski AP, Demory ML, Parsons JT, Parsons SJ, The src pathway as a therapeutic strategy, Drug Discovery Today: Therapeutic Strategies 2, 313-321, 2005
  13. Alvarez RH, Kantarjian HM, Cortes JE, The role of Src in solid and hematologic malignancies: development of new-generation Src inhibitors, Cancer 107, 1918-1929, 2006
  14. Hayes JD, Pulford DJ, The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance, Crit Rev Biochem Mol Biol 30, 445-600, 1995
  15. Di Pietro G, Magno L, Rios-Santos F, Glutathione S-transferases: an overview in cancer research, Expert Opin Drug Metab Toxicol 6, 153-170, 2010
  16. Baez S, Segura-Aguilar J, Widersten M, Johansson AS, Mannervik B, Glutathione transferases catalyse the detoxication of oxidized metabolites (o-quinones) of catecholamines and may serve as an antioxidant system preventing degenerative cellular processes, Biochem J 324, 25-28, 1997
  17. Scotlandi K, Remondini D, Castellani G, Manara MC, Nardi F, Cantiani